Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue

Journal of the National Cancer Institute

Volumn 91, Issue 24, 1999, Pages 2087-2095

  Galipeau, Patricia C ^a   Prevo, Laura J ^a   Sanchez, Carissa A ^a   Longton, Gary M ^a   Reid, Brian J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER GRADING; CHROMOSOME 17P; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME LOSS; ESOPHAGUS CANCER; FLOW CYTOMETRY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRECANCER; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 0033572286     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.24.2087     Document Type: Article

References (68)

1. Phillips RW, Wong RK. Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 1991;20: 791-816.
2. Reid BJ. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 1991;20:817-34.
3. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265: 1287-9.
4. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev 1992;1:265-9.
5. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83: 2049-53.
6. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 1996;7:322-7.
7. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105: 40-50.
8. Peters JH, Clark GW, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813-21; discussion 821-2.
9. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998;93: 1028-32.
10. Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984;87:927-33.
11. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
12. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
13. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441-6.
14. van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
15. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
16. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994;89:670-80.
17. Grimm I, Shaheen N, Bozymski EM. Surveillance for Barrett's esophagus: are we saving lives? Gastroenterology 1997;112:661-2.
18. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
19. Levine DS, Haggitt CR, Irvine S, Reid BJ. Natural history of high-grade dysplasia in Barrett's esophagus [abstract]. Gastroenterology 1996;110: A550.
20. Schnell T, Sontag SJ, Chejfec G, Kurucar C, O'Connell S, Levine G, et al. High grade dysplasia still is not an indication for surgery in patients with Barrett's esophagus: an update [abstract]. Gastroenterology 1998;114: A280.
21. Herbst JJ, Berenson MM, McCloskey DW, Wiser WC. Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). Gastroenterology 1978;75:683-7.
22. Pellish LJ, Hermos JA, Eastwood GL. Cell proliferation in three types of Barrett's epithelium. Gut 1980;21:26-31.
23. Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992;103:1769-76.
24. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119-29.
25. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93:1-11.
26. Fennerty MB, Sampliner RE, Way D, Riddell R, Steinbronn K, Garewal HS. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989;97:815-20.
27. Robaszkiewicz M, Reid BJ, Volant A, Cauvin JM, Rabinovitch PS, Gouerou H. Flow-cytometric DNA content analysis of esophageal squamous cell carcinomas. Gastroenterology 1991;101:1588-93.
28. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A 1996; 93:7081-4.
29. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopie surveillance of a cohort. Gastroenterology 1992;102:1212-9.
30. Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 1994;54:2292-5.
31. Barrett MT, Sanchez CA, Galipeau PC, Neshut K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867-73.
32. Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, et al. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 1991;51:5482-6.
33. Hammoud ZT, Kaleem Z, Cooper JD, Sundaresan RS, Patterson GA, Goodfellow PJ. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res 1996;56:4499-502.
34. Barrett MT, Galipeau PC, Sanchez CA, Emond MJ, Reid BJ. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene 1996;12:1873-8.
35. Dolan K, Garde J, Gosney J, Sissons M, Wright T, Kingsnorth AN, et al. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer 1998;78:950-7.
36. Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012-8.
37. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
38. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Russell SE. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 1995;55:3406-11.
39. Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997;57:2619-22.
40. Klump B. Hsieh CJ, Holzmann K, Gregor M, Forschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998;115:1381-6.
41. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
42. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992;326: 737-40.
43. Kishimoto Y, Sugio K, Hung JY, Virmani AK, McIntire DD, Minna JD, et al. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst 1995;87: 1224-9.
44. Paulson TG, Galipeau PC, Reid BJ. Loss of heterozygosity analysis using whole genome amplification, cell sorting and fluorescence-based PCR. Genome Res 1999;9:482-91.
45. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, DenBesten L, et al. Endoscopie biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988;94:81-90.
46. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
47. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
48. Prevo LJ, Sunchez CA, Galipeau PC, Reid BJ. p53-Mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59:4784-7.
49. Fleiss JL. Statistical methods for rates and proportions. New York (NY): John Wiley & Sons; 1981.
50. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
51. Blount PL, Meltzer SJ, Yin J, Huang Y, Krasna MJ, Reid BJ. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci USA 1993;90:3221-5.
52. Gleeson CM, Sloan JM, McManus DT, Maxwell P, Arthur K, McGuigan JA, et al. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer 1998;77:277-86.
53. Tarmin L, Yin J, Zhou X, Suzuki H, Jiang HY, Rhyu MG, et al. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res 1994;54:6094-6.
54. Zhou X, Tarmin L. Yin J, Jiang HY, Suzuki H, Rhyu MG, et al. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 1994;9:3737-41.
55. Muzeau F, Flejou JF, Thomas G, Hamelin R. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers. Int J Cancer 1997;72:27-30.
56. Neshat K, Sanchez CA, Galipeau PC, Cowan DS, Ramel S, Levine DS, et al. Barrett's esophagus: a model of human neoplastic progression. Cold Spring Harb Symp Quant Biol 1994;59:577-83.
57. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194:23-8.
58. An HX, Niederacher D, Picard F, van Roeyen C, Bender HG, Beckmann MW. Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer. Genes Chromosomes Cancer 1996;17:14-20.
59. Fujii H, Marsh C, Cairns P, Sidransky D, Gabrielson E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res 1996;56:1493-7.
60. Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998;58:5835-41.
61. Carder P, Wyllie AH, Purdie CA, Morris RG, White S, Piris J, et al. Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 1993;8:1397-401.
62. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72.
63. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366: 704-7.
64. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996;16:859-67.
65. Rabinovitch PS, Reid BJ, Haggitt RC, Norwood TH, Rubin CE. Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest 1989;60:65-71.
66. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. Mulation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 1992;52:3674-8.
67. Chung KY, Mukhopadhyay T, Kim J, Casson A, Ro JY, Goepfert H, et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 1993;53:1676-83.
68. Sozzi G, Miozzo M, Pastorino U, Pilotti S, Donghi R, Giarola M, et al. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res 1995;55:135-40.